LGVN Q3 2025 Earnings — Longeveron Inc. Revenue & Financial Results | Market Cap Arena

LGVNLongeveron Inc.

$20M

Q3 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$137,000-82.3% YoY

Gross Profit

$125,00091.2% margin

Operating Income

-$7M-5335.8% margin

Net Income

-$7M-5270.8% margin

EPS (Diluted)

$-0.39

QoQ Revenue Growth

-56.6%

Cash Flow

Operating Cash Flow

-$5M

Free Cash Flow

-$5M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$16M

Total Liabilities

$6M

Stockholders' Equity

$10M

Cash & Equivalents

$9M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$137,000	$773,000	-82.3%
Gross Profit	$125,000	$682,000	-81.7%
Operating Income	-$7M	-$5M	-57.2%
Net Income	-$7M	-$4M	-63.4%